Phase I trial of 4′-deoxydoxorubicin given weekly
- 1 December 1984
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 2 (4) , 369-374
- https://doi.org/10.1007/bf00171587
Abstract
Twenty-six patients with various solid tumors entered a Phase I trial with 4′ -Deoxydoxorubicin (Esorubicin, IMI-58), a new doxorubicin analogue. The drug was administered weekly i.v. for 3–4 weeks. Leukopenia proved to be dose limiting. The maximum tolerated dose (MTD) was reached at 20 mg/m2 weekly for 3 weeks. For Phase II trials, a weekly dose of 15 and 17.5 mg/m2 can be proposed for poor and good risk patients respectively. Non-hematologic toxicity was minimal. Phase II trials with this new anthracycline are warranted.Keywords
This publication has 6 references indexed in Scilit:
- Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin.Journal of Clinical Oncology, 1984
- Phase I trial with 4′-deoxydoxorubicin (esorubicin)Investigational New Drugs, 1983
- Antitumor activity in mice of 4′-Deoxydoxorubicin in comparison with doxorubicinEuropean Journal of Cancer and Clinical Oncology, 1983
- ANIMAL TOXICOLOGY FOR EARLY CLINICAL-TRIALS WITH ANTI-CANCER AGENTS1981
- NEW DOXORUBICIN ANALOGS ACTIVE AGAINST DOXORUBICIN-RESISTANT COLON-TUMOR XENOGRAFTS IN THE NUDE-MOUSE1980
- Synthesis and antitumor activity of 4'-deoxydaunorubicin and 4'-deoxyadriamycinJournal of Medicinal Chemistry, 1976